CMT-3. CollaGenex.

Barbara, Fingleton

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2004

Data sources: Europe PubMed Central

CMT-3. CollaGenex.

descriptionPublicationkeyboard_double_arrow_right Article 22 Mar 2004 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 4 (issn: 1472-4472,

Copyright policy )

Authors: Barbara, Fingleton;

pmid: 14763133

CMT-3. CollaGenex.

- Summary
- Subjects
- Metrics

Abstract

CMT-3 is an orally active matrix metalloprotease inhibitor, and one of a series of inhibitors of multiple proteases and cytokines, under development by CollaGenex. The compound is currently undergoing phase II trials for the potential treatment of cancer, in particular metastatic cancer and HIV-related Kaposi's sarcoma.

Related Organizations

Vanderbilt University Medical Center
United States

Keywords

Clinical Trials as Topic, Drugs, Investigational, Matrix Metalloproteinase Inhibitors, Matrix Metalloproteinases, Tetracyclines, Neoplasms, Animals, Humans, Technology, Pharmaceutical, Enzyme Inhibitors

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average